These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 20030193

  • 21. The immunopathology of multiple sclerosis: an overview.
    Lassmann H, Brück W, Lucchinetti CF.
    Brain Pathol; 2007 Apr; 17(2):210-8. PubMed ID: 17388952
    [Abstract] [Full Text] [Related]

  • 22. Multiple sclerosis: lessons from molecular neuropathology.
    Lassmann H.
    Exp Neurol; 2014 Dec; 262 Pt A():2-7. PubMed ID: 24342027
    [Abstract] [Full Text] [Related]

  • 23. [Mechanisms of Neurodegeneration in Multiple Sclerosis].
    Eliseeva DD, Zakharova MN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 Dec; 122(7. Vyp. 2):5-13. PubMed ID: 35912550
    [Abstract] [Full Text] [Related]

  • 24. Is multiple sclerosis a generalized disease of the central nervous system? An MRI perspective.
    Chard D, Miller D.
    Curr Opin Neurol; 2009 Jun; 22(3):214-8. PubMed ID: 19434770
    [Abstract] [Full Text] [Related]

  • 25. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
    Ziemssen T.
    J Neurol; 2005 Nov; 252 Suppl 5():v38-45. PubMed ID: 16254701
    [Abstract] [Full Text] [Related]

  • 26. Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis.
    Fetisova E, Chernyak B, Korshunova G, Muntyan M, Skulachev V.
    Curr Med Chem; 2017 Nov; 24(19):2086-2114. PubMed ID: 28302008
    [Abstract] [Full Text] [Related]

  • 27. Pathogenesis of tissue injury in MS lesions.
    Trapp BD, Bö L, Mörk S, Chang A.
    J Neuroimmunol; 1999 Jul 01; 98(1):49-56. PubMed ID: 10426362
    [Abstract] [Full Text] [Related]

  • 28. [New therapeutic strategies for remyelination in multiple sclerosis].
    Kremer D, Hartung HP, Stangel M, Küry P.
    Nervenarzt; 2015 Aug 01; 86(8):934-46. PubMed ID: 26122637
    [Abstract] [Full Text] [Related]

  • 29. Neuronal injury in chronic CNS inflammation.
    Zindler E, Zipp F.
    Best Pract Res Clin Anaesthesiol; 2010 Dec 01; 24(4):551-62. PubMed ID: 21619866
    [Abstract] [Full Text] [Related]

  • 30. Advances in the immune pathogenesis and treatment of multiple sclerosis.
    Huang D, Rae-Grant A.
    Cent Nerv Syst Agents Med Chem; 2009 Mar 01; 9(1):20-31. PubMed ID: 20021335
    [Abstract] [Full Text] [Related]

  • 31. Progressive multiple sclerosis.
    Bradl M, Lassmann H.
    Semin Immunopathol; 2009 Nov 01; 31(4):455-65. PubMed ID: 19730864
    [Abstract] [Full Text] [Related]

  • 32. The neuropathological basis of clinical progression in multiple sclerosis.
    Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O.
    Acta Neuropathol; 2011 Aug 01; 122(2):155-70. PubMed ID: 21626034
    [Abstract] [Full Text] [Related]

  • 33. Hypoxia-like tissue injury as a component of multiple sclerosis lesions.
    Lassmann H.
    J Neurol Sci; 2003 Feb 15; 206(2):187-91. PubMed ID: 12559509
    [Abstract] [Full Text] [Related]

  • 34. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.
    De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, Annunziata P, Bramanti P.
    Curr Med Chem; 2011 Feb 15; 18(12):1775-84. PubMed ID: 21466473
    [Abstract] [Full Text] [Related]

  • 35. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
    Recks MS, Bader J, Kaiser CC, Schroeter M, Fink GR, Addicks K, Kuerten S.
    Fortschr Neurol Psychiatr; 2011 Mar 15; 79(3):161-70. PubMed ID: 21394707
    [Abstract] [Full Text] [Related]

  • 36. White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.
    Longoni G, Brown RA, MomayyezSiahkal P, Elliott C, Narayanan S, Bar-Or A, Marrie RA, Yeh EA, Filippi M, Banwell B, Arnold DL, Canadian Pediatric Demyelinating Disease Network.
    Brain; 2017 May 01; 140(5):1300-1315. PubMed ID: 28334875
    [Abstract] [Full Text] [Related]

  • 37. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
    Vaknin-Dembinsky A, Weiner HL.
    J Neurol Sci; 2007 Aug 15; 259(1-2):90-4. PubMed ID: 17521671
    [Abstract] [Full Text] [Related]

  • 38. Progressive multiple sclerosis: from pathogenic mechanisms to treatment.
    Correale J, Gaitán MI, Ysrraelit MC, Fiol MP.
    Brain; 2017 Mar 01; 140(3):527-546. PubMed ID: 27794524
    [Abstract] [Full Text] [Related]

  • 39. Inflammatory demyelination and neurodegeneration in early multiple sclerosis.
    Charil A, Filippi M.
    J Neurol Sci; 2007 Aug 15; 259(1-2):7-15. PubMed ID: 17397873
    [Abstract] [Full Text] [Related]

  • 40. Pathological differences between white and grey matter multiple sclerosis lesions.
    Prins M, Schul E, Geurts J, van der Valk P, Drukarch B, van Dam AM.
    Ann N Y Acad Sci; 2015 Sep 15; 1351():99-113. PubMed ID: 26200258
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.